CDA | Evidence Driven
CDA | Evidence Driven

Imbruvica for Mantle Cell Lymphoma (relapsed/refractory)

Details

Files
Generic Name:
Ibrutinib
Project Status:
Complete
Therapeutic Area:
Mantle Cell Lymphoma (relapsed/refractory)
Manufacturer:
Janssen Inc.
Brand Name:
Imbruvica
Project Line:
Reimbursement Review
Project Number:
PC0073-000
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Strength:
140 mg capsule
Tumour Type:
Lymphoma
Indications:
Mantle Cell Lymphoma
Funding Request:
For the treatment of patients with relapsed/refractory mantle cell lymphoma (MCL)
Sponsor:
Janssen Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Ibrutinib (Imbruvica) Mantle Cell Lymphoma – pERC Final Recommendation Recommendation July 19, 2016 View PDF
Ibrutinib (Imbruvica) Mantle Cell Lymphoma – Final Clinical Guidance Report Guidance Reports July 19, 2016 View PDF
Ibrutinib (Imbruvica) Mantle Cell Lymphoma – Final Economic Guidance Report Guidance Reports July 19, 2016 View PDF
Ibrutinib (Imbruvica) Mantle Cell Lymphoma – pERC Initial Recommendation Initial Recommendation June 30, 2016 View PDF
Ibrutinib (Imbruvica) Mantle Cell Lymphoma – PAG Feedback on Initial Recommendation Feedback July 19, 2016 View PDF
Ibrutinib (Imbruvica) Mantle Cell Lymphoma – Manufacturer Feedback on Initial Recommendation Feedback July 19, 2016 View PDF
Ibrutinib (Imbruvica) Mantle Cell Lymphoma – Patient Advocacy Group Feedback on Initial Recommendation Feedback July 19, 2016 View PDF
Ibrutinib (Imbruvica) Mantle Cell Lymphoma – Patient Advocacy Group (LLSC-CCSN) Feedback on Initial Recommendation Feedback July 19, 2016 View PDF
Ibrutinib (Imbruvica) Mantle Cell Lymphoma – Patient Advocacy Group (LFC) COI Declarations COI Declarations July 19, 2016 View PDF
Ibrutinib (Imbruvica) Mantle Cell Lymphoma – Patient Advocacy Group (LLSC-CCSN) COI Declarations COI Declarations July 19, 2016 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : August 4, 2016